DBDamilola Samuel Bodun

Damilola Samuel Bodun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Damilola Samuel Bodun has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combining generative AI, machine learning, and structure-based drug design to identify potential VEGFR1 inhibitors

    by Opeyemi Isaac, Damilola Bodun, Ifeoluwa Aderibigbe, Bamise Joshua Oluwapelumi, Adedoyin John-Joy Owolade, Ibidun Isaac, Toheeb Balogun, Daniel O. Nwankwo, Chiamaka J. Ezeh, Fuwad Mohammed Kassim

  • Open Access

    Discovery of novel InhA inhibitors through structural bioinformatics and machine learning-driven QSAR screening of natural products

    by Godswill Imolele Anthony, Samuel Nzube Nwosu, Adedoyin John-Joy Owolade, Temitope Olubanjo Kehinde, Richard Gamah Teye, Samuel Eneojo Akor, Favour Segun Fabuyi, Ifeoma Roseline Nwafor, Precious Kelechi Oleh, Toluwalope Daniel Ilori, et al.

    Tuberculosis (TB) persists as a formidable global health challenge, particularly due to the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) variants that limit the effectiveness of existing therapies. These variants limit therapeutic options, prolong treatment duration and increase the risk of treatment failure. Additionally, the antitubercular drug discovery remains relatively limited; moreover, the rise in drug-resistant strains necessitates the need to identify and develop novel drug candidates that can overcome these resistance patterns. This study aims to design novel InhA inhibitors that can bind to and inhibit InhA and circumvent the resistance pathway in the KatG enzyme of Mycobacterium tuberculosis. We sourced an extensive library of 276 518 natural products from the LOTUS database and screened the compounds through a series of rigorous computational approaches such as drug-likeness filtration, molecular docking, MM-GBSA analysis, and ADMET prediction. We developed a machine learning model using a Message Passing Neural Network (MPNN). The MPNN was trained to predict bioactivity profiles of 31 597 natural products against the InhA enzyme. Molecular dynamics simulations further confirmed the stability of these interactions over 100-nanoseconds. Out of the screened compounds, four novel drug candidates exhibited strong binding affinities with binding energies of −12.204 kcal/mol, −11.926 kcal/mol, −11.624 kcal/mol, and −11.548 kcal/mol, respectively, surpassing the co-crystallized ligand (−8.895 kcal/mol), and the standard drug, Isoniazid (−12.204 kcal/mol). The top hit molecules demonstrated high and considerable structural stability during molecular dynamics simulations. Additionally, the pharmacokinetic profile of LTS0161715 exhibited low toxicity. positioning LTS0161715 for further investigation. These research findings elucidate the potential of direct InhA inhibitors, particularly LTS0161715, as a promising drug candidate for anti-tubercular drug development, while also highlighting the need for further optimization to enhance safety and efficacy.


  • Open Access

    Kaempferols from Echinacea purpurea demonstrate anti-cancer potential by targeting anexelekto in breast cancer therapy using chemoinformatics approach

    by Saviour God’swealth Usin, Daniel Ogbonnaya Nwankwo, Anas Haruna Ruggah, Adebesin Ayomide Oluwadarasimi, Ahad Ali, Timothy Oluwatimileyin Ayeni, Abass Abdulateef Ohilebo, Abdulsamad Omotayo Aiyelabegan, Opeyemi Christianah De Campos, Kayode Raheem Yomi, et al.

    Background Breast cancer is one of the most common cancer types among women, especially in developing and underdeveloped nations like Nigeria. Anexelekto (AXL) is one of the well-known proteins that is implicated in various cancer types, including breast cancer, and it remains one of the focuses of targeted therapy. However, several drugs have been identified as inhibitors of this oncogenic protein, but they often come with toxic concerns in addition to their unaffordability to people of low- or middle-income countries. Thus, there is a crucial need to identify pocket-friendly inhibitors with negligible side effects targeting AXL. Therefore, bioactive compounds from plants such as Echinacea purpurea may be a promising agent in this regard. Objective The study sought to investigate the potential of bioactive compounds derived from Echinacea purpurea to inhibit the AXL protein implicated in breast cancer. Methods Structural bioinformatics via molecular docking and density functional theory (DFT) analysis was utilised for the identification of novel AXL inhibitors from Echinacea purpurea bioactive compounds. The compounds were further subjected to pharmacokinetic and drug-likeness analysis. Results obtained from the compounds were compared against those of Foretinib, a known AXL inhibitor. Additionally, their complexes with AXL were subjected to a 100 ns molecular dynamics (MD) simulation analysis utilising the Desmond v2020-4 software in Schrödinger (Academic version) in a Linux environment. Results Among all favourable binding scores, Kaempferol-7-o-Neohesperidoside, Kaempferol 3-gentiobioside-7-rhamnoside, and Kaempferol 3-o-beta-d-glucopyranosyl-7-o-alpha-L-rhamnopyranoside showed the highest binding score of -9.2, -8.9, and − 8.6 Kcal/mol, respectively, compared to Foretinib (-8.1 Kcal/mol). Stigmasterol and β-sitosterol also showed a higher binding affinity and binding score of -8.4 and − 8.3 Kcal/mol, respectively, against the AXL compared to the standard drug. DFT analysis revealed that Kaempferol 3-o-beta-d-glucopyranosyl-7-o-alpha-L-rhamnopyranoside has the highest LUMO-HOMO gap of -4.354 eV, suggesting greater potential for electron donation and high drug-enzyme reactivity. Also, the pharmacokinetic profiling of the selected compounds is favourable. Findings from MD simulation showed that the protein-ligand complexes formed by these compounds maintained structural stability, compactness, and low atomic fluctuations throughout a 100-ns simulation period. Conclusion In silico studies show that E. purpurea-derived compounds, especially Kaempferol 3-o-beta-d-glucopyranosyl-7-o-alpha-L-rhamnopyranoside, have better inhibitory potential against AXL and better pharmacokinetic profiles when compared with Foretinib. These compounds are thus proposed as novel AXL inhibitors for the treatment of breast cancer. Further, in vivo studies are needed to confirm the potency of the studied compounds.


  • De novo design and bioactivity prediction of mitotic kinesin Eg5 inhibitors using MPNN and LSTM-based transfer learning

    by Damilola Samuel Bodun, Isiaka O. Ibrahim, Mujeebat Bashiru, Rachael Oluwakamiye Abolade, Wilberforce K. Ndarawit, Adedoyin John-Joy Owolade, Adegbenro Temitope, Ibeh John Somtochukwu, Ezekiel Abiola Olugbogi, Katukoliya Gamage Anuththara Samadhi, et al.


  • Synthesis, in silico and in vitro antimicrobial efficacy of some amidoxime-based benzimidazole and benzimidamide derivatives

    by Gbolahan O. Oduselu, Olayinka O. Ajani, Temitope A. Ogunnupebi, Oluwadunni F. Elebiju, Damilola S. Bodun, Oluwabukayo Toluwunmiju Opebiyi, Ezekiel Adebiyi

    Summary of the synthesis, computational analysis, and in vitro antimicrobial evaluation of amidoxime-based benzimidazole and benzimidamide derivatives.


  • Open Access

    De Novo Design and Bioactivity Prediction of Mitotic Kinesin Eg5 Inhibitors Using MPNN and LSTM-Based Transfer Learning

    by Damilola Bodun, Isiaka Ibrahim, Mujeebat Bashiru, Rachael Oluwakamiye Abolade, Wilberforce K. Ndarawit, Adedoyin John-Joy Owolade, Temitope Adegbenro, John Somtochukwu Ibeh, Ezekiel Abiola Olugbogi, Katukoliya Gamage Anuththara Samadhi, et al.

    Breast cancer, the most commonly diagnosed disease worldwide, has been linked to the overexpression of the kinesin Eg5 protein, a spindle motor protein crucial for the assembly and maintenance of the bipolar spindle during mitosis. This makes Eg5 an attractive therapeutic target for tumor treatment. To address the urgent need for effective treatments for this life-threatening illness, we utilized generative AI to design novel and potential inhibitors of this protein. In this study, a generative LSTM model was pretrained on SMILES data from ChEMBL and subsequently fine-tuned using SMILES of compounds with reported activity against the Eg5 protein. The fine-tuned model generated valid compounds, which were screened using a machine learning model, drug-likeness filters, molecular docking, and molecular dynamics (MD) simulations conducted over 200 ns. Five novel compounds with better binding affinities to Eg5 compared to the co-crystallized ligand were identified. The top compound, Compound 103 (a bioisostere of the co-crystallized ligand), demonstrated a significantly improved binding free energy (-82.68 kcal/mol) compared to the co-crystallized ligand (-76.98 kcal/mol), as determined by MM-GBSA calculations. ADMET predictions and MD simulations further confirmed that the top compounds interacted effectively with the target protein and exhibited drug-like properties. This study shows the potential of generative AI to explore our vast chemical space and find promising drug candidates. However, further in vitro and in vivo studies are needed to confirm the predicted biological effects of the top compounds.

  • In-silico-based lead optimization of hit compounds targeting mitotic kinesin Eg5 for cancer management

    by Damilola S. Bodun, Damilola A. Omoboyowa, Victor F. Olofinlade, Adeyemi O. Ayodeji, Andrea Mauri, Uchechukwu C. Ogbodo, Toheeb A. Balogun

    Lead optimization is vital for turning hit compounds into therapeutic drugs. This study builds upon a prior in silico research, where the hit compounds had better binding affinity and stability compared to a reference drug. Using a genetic algorithm, 12,500 analogs of the top compounds from the prior study were generated. Virtual screening was done using a quantitative structure-activity relationship (QSAR) model. Top analogs, selected based on pChembL values below 6.000nM, underwent molecular docking targeting Human Eg5. The top five analogs from this study (Compound 9794, Compound 8592, Compound 9786, Compound 2744, and Compound 3246) demonstrated strong binding energies and interactions with key amino acids (GLU 116, GLU 117, and ARG 119). MMGBSA analysis revealed comparable affinities to the co-crystallized ligand, suggesting the top analogs’ potential as Human Eg5 inhibitors. Induced fit docking highlighted Compound 9786’s superior efficacy. Quantum Polarized Ligand Docking indicated promising scores for Compounds 8592 and 9786. ADMET predictions offered insights into pharmacological properties, with all compounds predicted to be HIA-positive and non-carcinogenic. Further MD simulation study confirms the stability of the top compounds in the active site of Eg5. This study shows the significance of integrated strategies in drug design. However, in vitro and in vivo studies should be conducted for these promising candidates to confirm their efficacy as Eg5 inhibitors.


  • Machine Learning-Based Drug Repositioning of Novel Human Aromatase Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation

    by Damilola Samuel Bodun, Adeniyi Ayinde Abdulwahab, Temitope Ibukunoluwa Adegbenro, Emidun Olayinka Chidinma, Samuel Aduramurewa Osunnaya, Mary Oluwatominsin Alonge, Zainab Olaide Diyaolu, Muhammad Temitope Abdulazeez, Rachael Oluwakamiye Abolade

    In the continuous search for potential drug-like molecules for diseases, drug repurposing offers a solution by identifying new roles for the existing drugs. For breast cancer, which is the leading cause of death among women, discovering a new drug with fewer side effects can take more than a year, and drug repurposing provides a faster alternative. In this study, we used machine learning (ML) and structure-based screening to evaluate molecules from the ChEMBL library against Human Aromatase, an enzyme that is involved in the conversion of androgens to estrogen. The virtual screening output identified 148 potential compounds. These compounds were further subjected to detailed structure-based virtual screening, followed by assessment of induced fit docking, quantum-based docking and ADMET properties. The top compound, CHEMBL502014 and the co-crystallized ligand (reference) were evaluated through MD simulations for 100 ns. The results indicated that the CHEMBL502014-Aromatase complex demonstrated better conformational stability throughout the simulation compared to the reference ligand. Based on these analyses, we propose CHEMBL502014 and other top compounds with known activities against various proteins as potential candidates for anti-cancer activity against breast cancer. These compounds should be further evaluated using experimental assays to confirm their effectiveness against breast cancer.


  • Open Access

    Molecular mechanics and dynamics simulation of CD-47/SIRPα blockade study: A computational study on overcoming immunotherapeutic resistance in pancreatic ductal adenocarcinoma

    by Oluwatosin A. Saibu, Temitope M. Ajayi, Damilola A. Omoboyowa, Oladapo O. Oladipo, Sodiq O. Hammed, Tope T. Odunitan, Adenrele T. Oluwafemi, Aderonke J. Adejuyigbe, Gideon O. Aloba, Toheeb A. Balogun, et al.

    The sting of pancreatic ductal adenocarcinoma remains an irksome burden to the human populace. The focus of recent research has switched from finding the perfect medicinal medication to blocking immunological checkpoint proteins such as the signal regulating protein alpha-cluster of differentiation 47 (SIRPα-CD47). The search for CD47/SIRPα inhibitors with excellent oral bioavailability and permeability continues to elude researchers. This research aims to identify bioactive molecules with negligible side as inhibitor SIRPα-CD47 signaling cascade. Bioactive flavonoids from African medicinal plants were virtually screened against the SIRP-α binding site of CD47 using Schrodinger suite 2017-v1. The docking score was validated and complex stability performed using Gromacs. Among the bioactive flavonoids, five (5) compounds were predicted as potent inhibitors of CD47 with pelargonidin observed to have the best binding affinity of −6.715 kcal/mol. Validation using QSAR and pharmacophore modeling further confirm the interaction with predicted pIC50 range of 5.981 to 6.841 µM and fitness score of 1.109 to 1.530. Drug-likeness prediction revealed that all hit compounds obey Lipinski’s rule of five. The MD simulation result predicted the stability of pelargonidin and malvidin comparable to the standard drug NCGC00138783. The quantum mechanics estimation revealed that, the hit compounds have proton donating and accepting ability hence, they possess inhibitory potential. From the molecular docking, post-docking and MD simulation analyzes of this study, Pelargonidin, malvidin and Peonidin were proposed as suitable candidates that could be probed further for developing a new target-specific immunotherapeutic agent against PDAC.